Your Hormones Just Got New Treatment Options: Here's What Changed in 2025

The hormone treatment landscape shifted dramatically in 2025, with new approvals for adrenal conditions, expanded access to diabetes technology, and surprising discoveries about thyroid cancer risk. These developments offer fresh hope for millions dealing with endocrine disorders, from rare adrenal insufficiency to common thyroid imbalances.

What New Hormone Treatments Got FDA Approval?

The Food and Drug Administration (FDA) cleared several game-changing treatments this year. Eton Pharmaceuticals received approval for hydrocortisone oral solution (KHINDIVI) specifically designed for children aged 5 and older with adrenocortical insufficiency—the first liquid formulation approved for this condition. This ready-to-use 1 mg/mL solution eliminates the need for pill-splitting and provides accurate dosing for young patients who struggle with swallowing pills.

Meanwhile, Recordati expanded the label for osilodrostat (Isturisa) to include adults with endogenous Cushing's syndrome who aren't surgical candidates or for whom surgery wasn't successful. Previously approved only for Cushing's disease, this broader indication was supported by data from the LINC 3 and LINC 4 trials showing sustained cortisol reduction and clinical improvement.

How Are Diabetes Medications Affecting Thyroid Health?

A concerning pattern emerged regarding glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy and thyroid cancer diagnoses. Analysis of nearly 352,000 adults with type 2 diabetes found that GLP-1 RA therapy raised the risk of new thyroid cancer diagnosis within the first year of treatment, compared with other diabetic medications. However, researchers noted these increases disappeared in later follow-up periods, linking the first-year spike to increased screening rates rather than the medication actually causing cancer.

The absolute risk remained low, but this finding highlights the importance of monitoring thyroid health when starting these popular weight-loss and diabetes medications. "The first-year increase in diagnoses appears linked to increased screening rates," researchers noted in their analysis of the data.

What Advances Happened in Hormone Monitoring Technology?

Continuous glucose monitoring (CGM) technology took a major leap forward when the FDA cleared Dexcom's G7 15-day system in April 2025, making it the longest-lasting and most accurate CGM approved in the United States. Based on clinical data showing a mean absolute relative difference (MARD) of 8.0%, this system offers excellent accuracy for people managing diabetes.

The new features include:

• Extended Wear: 15-day sensor life with a 12-hour grace period for sensor changes
• Smart Integration: Apple Watch compatibility for easy glucose monitoring
• Durability: Waterproof sensors that withstand daily activities
• Pump Compatibility: Designed to work with insulin pump systems for comprehensive diabetes management

Dexcom plans to launch the system in the United States by late 2025, with compatibility testing for insulin pump systems already underway.

What's Coming Next for Hormone Treatments?

Several promising developments are in the pipeline. Novo Nordisk submitted a new drug application (NDA) for a once-daily 25 mg oral formulation of semaglutide for chronic weight management, which could become the first oral GLP-1 therapy approved for obesity. The FDA accepted this submission in May 2025, with a decision expected in the fourth quarter of 2025.

For rare hormone conditions, Crinetics Pharmaceuticals announced positive results from their Phase 2 TouCAHn trial investigating atumelnant for classic congenital adrenal hyperplasia (CAH) and adrenocorticotropic hormone (ACTH)-dependent Cushing's syndrome. This novel oral ACTH receptor antagonist achieved rapid reductions in key CAH biomarkers, including up to 80% reduction in mean androstenedione levels.

Additionally, Veru Pharmaceuticals reported that enobosarm, a selective androgen receptor modulator (SARM), successfully protected lean muscle mass in patients receiving semaglutide for weight reduction. This addresses a common concern about muscle loss during rapid weight loss with GLP-1 medications.